+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Liver Diseases Therapeutics Market Research Report by Treatment, End-user, and Region - Global Forecast to 2026 - Cumulative Impact of COVID-19

  • ID: 4904957
  • Report
  • October 2021
  • Region: Global
  • 189 pages
  • 360iResearch™
UP TO OFF
until Jan 01st 2022
Global Liver Diseases Therapeutics Market is Projected to Reach USD 21.18 Billion by 2026, Registering a CAGR of 7.96%

FEATURED COMPANIES

  • AstraZeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Gilead Science Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • MORE
The Global Liver Diseases Therapeutics Market size was estimated at USD 13.37 billion in 2020, is expected to reach USD 14.39 billion in 2021, and projected to grow at a CAGR of 7.96% reaching USD 21.18 billion by 2026.



Market Statistics


The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2026 are considered the forecast period.

Market Segmentation & Coverage


This research report categorizes the Liver Diseases Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

  • Based on Treatment, the market was studied across Anti Viral Drugs, Chemotherapy Drugs, Corticosteroids, Immunoglobulin, Immunosuppressant Drugs, and Targeted Therapy.
  • Based on End-user, the market was studied across Ambulatory Surgery Centers and Hospitals.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Cumulative Impact of COVID-19


COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. The analyst's ongoing research amplifies their research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.

Competitive Strategic Window


The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.

FPNV Positioning Matrix


The FPNV Positioning Matrix evaluates and categorizes the vendors in the Liver Diseases Therapeutics Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Market Share Analysis


The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario


The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.

Company Usability Profiles


The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Liver Diseases Therapeutics Market, including AstraZeneca plc, Bayer AG, F. Hoffmann-La Roche AG, Gilead Science Inc., GlaxoSmithKline plc, Johnson & Johnson Private Limited, Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Liver Diseases Therapeutics Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Liver Diseases Therapeutics Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Liver Diseases Therapeutics Market?
4. What is the competitive strategic window for opportunities in the Global Liver Diseases Therapeutics Market?
5. What are the technology trends and regulatory frameworks in the Global Liver Diseases Therapeutics Market?
6. What is the market share of the leading vendors in the Global Liver Diseases Therapeutics Market?
7. What modes and strategic moves are considered suitable for entering the Global Liver Diseases Therapeutics Market?
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Gilead Science Inc.
  • GlaxoSmithKline plc
  • Merck & Co. Inc.
  • MORE
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary
3.1. Introduction

4. Market Overview
4.1. Introduction
4.2. Cumulative Impact of COVID-19

5. Market Dynamics
5.1. Introduction
5.2. Drivers
5.2.1. Surge in the incidences of lover diseases worldwide
5.2.2. Increasing government and private organizations initiatives toward awareness and vaccination programs
5.2.3. Changing lifestyles such as consumption of alcohol and smoking
5.3. Restraints
5.3.1. Concerns over probable side effects of the medication
5.4. Opportunities
5.4.1. Ongoing research and development activities for prevention and cure of liver diseases
5.4.2. Increasing patent expiration of therapeutics
5.5. Challenges
5.5.1. Strict government regulations and high cost involved in R&D

6. Liver Diseases Therapeutics Market, by Treatment
6.1. Introduction
6.2. Anti Viral Drugs
6.3. Chemotherapy Drugs
6.4. Corticosteroids
6.5. Immunoglobulin
6.6. Immunosuppressant Drugs
6.7. Targeted Therapy

7. Liver Diseases Therapeutics Market, by End-user
7.1. Introduction
7.2. Ambulatory Surgery Centers
7.3. Hospitals

8. Americas Liver Diseases Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States

9. Asia-Pacific Liver Diseases Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand

10. Europe, Middle East & Africa Liver Diseases Therapeutics Market
10.1. Introduction
10.2. France
10.3. Germany
10.4. Italy
10.5. Netherlands
10.6. Qatar
10.7. Russia
10.8. Saudi Arabia
10.9. South Africa
10.10. Spain
10.11. United Arab Emirates
10.12. United Kingdom

11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis
11.3. Market Share Analysis, by Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion

12. Company Usability Profiles
12.1. AstraZeneca plc
12.2. Bayer AG
12.3. F. Hoffmann-La Roche AG
12.4. Gilead Science Inc.
12.5. GlaxoSmithKline plc
12.6. Johnson & Johnson Private Limited
12.7. Merck & Co. Inc.
12.8. Novartis AG
12.9. Pfizer Inc.
12.10. Sanofi

13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

List of Figures
Figure 1. Global Liver Diseases Therapeutics Market Size, 2020 vs 2026 (USD Billion)
Figure 2. Global Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 3. Global Liver Diseases Therapeutics Market: Market Dynamics
Figure 4. Global Liver Diseases Therapeutics Market Size, by Treatment, 2020 vs 2026 (%)
Figure 5. Global Liver Diseases Therapeutics Market Size, by Treatment, 2020 vs 2026 (USD Billion)
Figure 6. Competitive Strategic Window for Global Liver Diseases Therapeutics Market Size, by Treatment, 2026
Figure 7. Global Liver Diseases Therapeutics Market Size, by Anti Viral Drugs, 2018-2026 (USD Billion)
Figure 8. Global Liver Diseases Therapeutics Market Size, by Anti Viral Drugs, by Region, 2020 vs 2026 (USD Billion)
Figure 9. Global Liver Diseases Therapeutics Market Size, by Chemotherapy Drugs, 2018-2026 (USD Billion)
Figure 10. Global Liver Diseases Therapeutics Market Size, by Chemotherapy Drugs, by Region, 2020 vs 2026 (USD Billion)
Figure 11. Global Liver Diseases Therapeutics Market Size, by Corticosteroids, 2018-2026 (USD Billion)
Figure 12. Global Liver Diseases Therapeutics Market Size, by Corticosteroids, by Region, 2020 vs 2026 (USD Billion)
Figure 13. Global Liver Diseases Therapeutics Market Size, by Immunoglobulin, 2018-2026 (USD Billion)
Figure 14. Global Liver Diseases Therapeutics Market Size, by Immunoglobulin, by Region, 2020 vs 2026 (USD Billion)
Figure 15. Global Liver Diseases Therapeutics Market Size, by Immunosuppressant Drugs, 2018-2026 (USD Billion)
Figure 16. Global Liver Diseases Therapeutics Market Size, by Immunosuppressant Drugs, by Region, 2020 vs 2026 (USD Billion)
Figure 17. Global Liver Diseases Therapeutics Market Size, by Targeted Therapy, 2018-2026 (USD Billion)
Figure 18. Global Liver Diseases Therapeutics Market Size, by Targeted Therapy, by Region, 2020 vs 2026 (USD Billion)
Figure 19. Global Liver Diseases Therapeutics Market Size, by End-user, 2020 vs 2026 (%)
Figure 20. Global Liver Diseases Therapeutics Market Size, by End-user, 2020 vs 2026 (USD Billion)
Figure 21. Competitive Strategic Window for Global Liver Diseases Therapeutics Market Size, by End-user, 2026
Figure 22. Global Liver Diseases Therapeutics Market Size, by Ambulatory Surgery Centers, 2018-2026 (USD Billion)
Figure 23. Global Liver Diseases Therapeutics Market Size, by Ambulatory Surgery Centers, by Region, 2020 vs 2026 (USD Billion)
Figure 24. Global Liver Diseases Therapeutics Market Size, by Hospitals, 2018-2026 (USD Billion)
Figure 25. Global Liver Diseases Therapeutics Market Size, by Hospitals, by Region, 2020 vs 2026 (USD Billion)
Figure 26. Americas Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 27. Argentina Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 28. Brazil Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 29. Canada Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 30. Mexico Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 31. United States Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 32. Asia-Pacific Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 33. Australia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 34. China Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 35. India Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 36. Indonesia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 37. Japan Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 38. Malaysia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 39. Philippines Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 40. Singapore Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 41. South Korea Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 42. Taiwan Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 43. Thailand Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 44. Europe, Middle East & Africa Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 45. France Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 46. Germany Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 47. Italy Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 48. Netherlands Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 49. Qatar Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 50. Russia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 51. Saudi Arabia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 52. South Africa Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 53. Spain Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 54. United Arab Emirates Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 55. United Kingdom Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Figure 56. Global Liver Diseases Therapeutics Market: FPNV Positioning Matrix
Figure 57. Global Liver Diseases Therapeutics Market: Share, by Key Player, 2020
Figure 58. Competitive Scenario Analysis in Global Liver Diseases Therapeutics Market, by Type

List of Tables
Table 1. Global Liver Diseases Therapeutics Market: Market Segmentation & Coverage
Table 2. United States Dollar Exchange Rate, 2016–2020
Table 3. Global Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 4. Global Liver Diseases Therapeutics Market Size, by Treatment, 2018-2026 (USD Billion)
Table 5. Global Liver Diseases Therapeutics Market Size, by Anti Viral Drugs, by Region, 2018-2026 (USD Billion)
Table 6. Global Liver Diseases Therapeutics Market Size, by Chemotherapy Drugs, by Region, 2018-2026 (USD Billion)
Table 7. Global Liver Diseases Therapeutics Market Size, by Corticosteroids, by Region, 2018-2026 (USD Billion)
Table 8. Global Liver Diseases Therapeutics Market Size, by Immunoglobulin, by Region, 2018-2026 (USD Billion)
Table 9. Global Liver Diseases Therapeutics Market Size, by Immunosuppressant Drugs, by Region, 2018-2026 (USD Billion)
Table 10. Global Liver Diseases Therapeutics Market Size, by Targeted Therapy, by Region, 2018-2026 (USD Billion)
Table 11. Global Liver Diseases Therapeutics Market Size, by End-user, 2018-2026 (USD Billion)
Table 12. Global Liver Diseases Therapeutics Market Size, by Ambulatory Surgery Centers, by Region, 2018-2026 (USD Billion)
Table 13. Global Liver Diseases Therapeutics Market Size, by Hospitals, by Region, 2018-2026 (USD Billion)
Table 14. Americas Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 15. Argentina Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 16. Brazil Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 17. Canada Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 18. Mexico Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 19. United States Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 20. Asia-Pacific Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 21. Australia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 22. China Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 23. India Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 24. Indonesia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 25. Japan Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 26. Malaysia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 27. Philippines Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 28. Singapore Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 29. South Korea Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 30. Taiwan Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 31. Thailand Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 32. Europe, Middle East & Africa Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 33. France Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 34. Germany Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 35. Italy Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 36. Netherlands Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 37. Qatar Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 38. Russia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 39. Saudi Arabia Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 40. South Africa Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 41. Spain Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 42. United Arab Emirates Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 43. United Kingdom Liver Diseases Therapeutics Market Size, 2018-2026 (USD Billion)
Table 44. Global Liver Diseases Therapeutics Market: Scores
Table 45. Global Liver Diseases Therapeutics Market: Business Strategy
Table 46. Global Liver Diseases Therapeutics Market: Product Satisfaction
Table 47. Global Liver Diseases Therapeutics Market: Ranking
Table 48. Global Liver Diseases Therapeutics Market: Share, by Key Player, 2020
Table 49. Global Liver Diseases Therapeutics Market: Merger & Acquisition
Table 50. Global Liver Diseases Therapeutics Market: Agreement, Collaboration & Partnership
Table 51. Global Liver Diseases Therapeutics Market: New Product Launch & Enhancement
Table 52. Global Liver Diseases Therapeutics Market: Investment & Funding
Table 53. Global Liver Diseases Therapeutics Market: Award, Recognition & Expansion
Table 54. Global Liver Diseases Therapeutics Market: License & Pricing
Note: Product cover images may vary from those shown
  • AstraZeneca plc
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Gilead Science Inc.
  • GlaxoSmithKline plc
  • Johnson & Johnson Private Limited
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll